Caplin Point Laboratories share price
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,249.10.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹16,890 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 25.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 4.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.36%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 76,90447.0% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 12 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹610 Crup 1.70%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹179 Crup 3.59%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 29.3%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 8 Nov | Dec 2024Filed 7 Feb | Mar 2025Filed 10 Jun | Jun 2025Filed 7 Aug | Sep 2025Filed 5 Nov | Dec 2025Filed 5 Feb | Mar 2026Filed 14 May | Jun 2026Filed 12 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 |
| Net profit | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 27.1% | 28.4% | 28.9% | 29.5% | 30.0% | 30.6% | 28.8% | 29.3% |
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Rest of the WorldRest of the World, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,734 Crup 9.53%79.3%
- USAUSA, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹453 Crup 27.89%20.7%
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 64% of 2,480 trading days over the last 10 years.
At or below today's level on 55% of 1,880 trading days since Nov 2018.
At or below today's level on 77% of 1,880 trading days since Nov 2018.
At or below today's level on 54% of 2,470 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −24.2% | +19.5% | −37.1% | 0.5% |
| 3 years | +36.6% | +19.4% | +14.1% | 0.4% |
| 5 years | +30.6% | +21.4% | +7.2% | 0.5% |
Mutual funds holding it
64 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 49 of the 54 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 24
- CutCut. Funds that held fewer shares than at the end of the month before.
- 30
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 9
| Fund | |||
|---|---|---|---|
 UTI Small Cap FundUTI Mutual Fund | 3,60,882 | 1.87% | ₹98.0 Cr |
| UTI Large & Mid Cap FundUTI Mutual Fund | 2,48,238 | 1.08% | ₹67.4 Cr |
| UTI Aggressive Hybrid FundUTI Mutual Fund | 1,91,227 | 0.80% | ₹51.9 Cr |
| UTI Healthcare FundUTI Mutual Fund | 1,59,030 | 3.02% | ₹43.2 Cr |
| UTI Retirement FundUTI Mutual Fund | 79,628 | 0.47% | ₹21.6 Cr |
 Nippon India Nifty Smallcap 250 Index FundNippon India Mutual Fund | 31,032 | 0.24% | ₹8.43 Cr |
 Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETFMirae Asset Mutual Fund | 24,442 | 0.71% | ₹6.64 Cr |
 HDFC Nifty Smallcap 250 ETFHDFC Mutual Fund | 24,355 | 0.24% | ₹6.62 Cr |
 Quantum Small Cap FundQuantum Mutual Fund | 16,572 | 1.72% | ₹4.50 Cr |
 SBI Nifty Smallcap 250 Index FundSBI Mutual Fund | 15,764 | 0.24% | ₹4.28 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Caplin Point Laboratories in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Rubicon ResearchRUBICON | 23,578 | 81.8 | 18.3 | 52.2 | – | – | 22.4% | 25.8% | 0.11% |
 Granules IndiaGRANULES | 21,679 | 32.7 | – | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.22% |
 Cohance LifesciencesCOHANCE | 17,211 | 162.0 | 4.4 | 54.8 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 Shilpa MedicareSHILPAMED | 16,904 | 56.9 | 6.5 | 36.6 | +27.9% | +167.6% | 12.0% | 10.9% | 0.07% |
 PfizerPFIZER | 16,525 | 22.5 | 3.9 | 14.2 | +10.7% | −9.1% | 17.5% | 21.0% | 2.08% |
 Natco PharmaNATCOPHARM | 15,534 | 13.6 | – | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.57% |
 Alivus Life SciencesALIVUS | 15,354 | 25.5 | 4.6 | 18.3 | +7.9% | +21.7% | 19.6% | 22.7% | 0.40% |
 Onesource Specialty PharmaONESOURCE | 15,299 | – | 2.6 | 48.6 | +27.2% | – | −0.8% | 0.8% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 18 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹4.00 |
| 29 May 2026 | Interim | ₹4.00 |
| 12 Sep 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 30 May 2025 | Interim | ₹3.00 |
| 23 Sep 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.50 |
| 31 May 2024 | Interim | ₹2.50 |
Latest announcements
Routine notices left out.Share news and announcements
Sep 2026
24 Sep · Legal
The exchange asked on 24 Sep 2026
4 Sep · Updates
Caplin Point Laboratories share price by year
Each calendar year to 2025.Caplin Point Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,838.10 | −26.5% | 2,583.25 | 1,713.80 |
| 2024 | 2,500.65 | +84.4% | 2,600.15 | 1,240.40 |
| 2023 | 1,356.15 | +90.1% | 1,421.10 | 584.15 |
| 2022 | 713.30 | −16.9% | 872.45 | 633.90 |
| 2021 | 858.20 | +69.5% | 956.00 | 403.45 |
| 2020 | 506.40 | +68.3% | 629.85 | 193.05 |
| 2019 | 300.85 | −21.2% | 454.60 | 288.25 |
| 2018 | 382.00 | −39.5% | 676.95 | 360.70 |
| 2017 | 631.45 | +84.0% | 758.55 | 335.60 |
| 2016 | 343.15 | +21.6% | 404.35 | 182.73 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 2,249.10 | 2,265.00 | 2,194.50 | 2,222.00 | 2,220.45 | 76,904 | 47.0% |
| 22 Oct 2026 | 2,197.60 | 2,263.00 | 2,176.20 | 2,249.10 | 2,227.37 | 73,971 | 43.9% |
| 21 Oct 2026 | 2,263.80 | 2,274.10 | 2,210.00 | 2,221.60 | 2,238.58 | 81,831 | 49.3% |
| 19 Oct 2026 | 2,301.30 | 2,322.10 | 2,255.00 | 2,258.80 | 2,284.01 | 70,397 | 45.0% |
| 16 Oct 2026 | 2,324.90 | 2,335.90 | 2,291.00 | 2,301.30 | 2,312.23 | 64,351 | 49.1% |
| 15 Oct 2026 | 2,338.20 | 2,361.90 | 2,248.10 | 2,301.80 | 2,311.32 | 1,32,807 | 42.8% |
| 14 Oct 2026 | 2,375.00 | 2,409.00 | 2,321.00 | 2,338.20 | 2,351.33 | 1,08,532 | 38.5% |
| 13 Oct 2026 | 2,419.80 | 2,425.60 | 2,325.20 | 2,361.60 | 2,358.80 | 1,67,353 | 43.5% |
| 12 Oct 2026 | 2,423.10 | 2,460.70 | 2,385.00 | 2,419.80 | 2,419.15 | 2,28,285 | 40.2% |
| 9 Oct 2026 | 2,541.00 | 2,576.40 | 2,431.10 | 2,460.80 | 2,478.96 | 1,88,948 | 43.5% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 19 Oct 2016 | Split | 0.2000 | Each share became 5. |
About Caplin Point Laboratories
Caplin Point Laboratories Limited is a pharmaceutical company. It manufactures and markets finished formulations, manufactures active pharmaceutical ingredients, and carries out research and development and clinical research. Its business model mostly serves emerging markets of Latin America and Africa, and it has a growing presence in regulated markets such as the USA.
It offers more than 650 formulations across 36 therapeutic areas, including tablets, capsules, liquid orals, ointments, injectables and ophthalmic products. The group is organised by subsidiary. Caplin Steriles Limited makes injectable and ophthalmic products for regulated markets. Caplin One Labs Limited makes oncology formulations. Caplin Point Far East Limited, a wholly owned subsidiary in Hong Kong, holds the Latin American subsidiaries and consolidates the emerging market distribution network. Caplin Steriles USA Inc. is a subsidiary of Caplin Steriles Limited, and it reaches over 14,300 hospitals, pharmacies and clinics in the USA.
Manufacturing sites are at Suthukeny (Puducherry), Kakkalur (Chennai), Gummidipoondi (Chennai) and Visakhapatnam (Andhra Pradesh). Some products are made at approved outsourced sites in India and China. Products are registered in more than 55 countries.
It was incorporated in 1990. Its founder, C.C. Paarthipan, started a partnership venture in 1987 to make external ointments and creams. The company became a public limited company in 1993 and listed on the Indian stock exchanges in 1994. From 2000 it moved into Latin America and Francophone Africa. In 2022 it acquired an API plant in Visakhapatnam.
- Legal name
- Caplin Point Laboratories Limited
- NSE symbol
- CAPLIPOINT
- BSE code
- 524742
- ISIN
- INE475E01026
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Feb 1995 on BSE, Jun 2014 on NSE
- Face value
- ₹2
- CIN
- L24231TN1990PLC019053
- Corporate identity number, the registrar of companies' code for it